|
|
|
A new drug that shows robust anti-tumour activity in a preclinical mouse model of cancer, is reported in Nature. The molecule, called MLN4924, is currently being evaluated in several phase I clinical trials.
MLN4924 suppresses the growth of human cancer cells that have been transplanted into mice, Teresa Soucy and colleagues report. It works by blocking an upstream step in a major intracellular pathway that regulates protein degradation. Another inhibitor of the pathway that targets the proteasome, bortezomib (Velcade), is already in clinical use for certain types of blood cancer. Bortezomib works by inhibiting a downstream step in the same pathway, so MLN4924 may have different clinical potential. The new molecule also works by a different mechanism. It deregulates the part of the cell cycle, called S-phase, where DNA synthesis occurs. This results in DNA damage and the induction of programmed cell death or cancer cell 'suicide'. CONTACT
Teresa Soucy (Millennium Pharmaceuticals, Cambridge, MA, USA)
E-mail: teresa.soucy@mpi.com (C) Nature press release.
Message posted by: Trevor M. D'Souza
|
|
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...
|